Bastion Y, Berger F, Bryon P A, Felman P, Ffrench M, Coiffier B
Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Ann Oncol. 1991 Feb;2 Suppl 2:123-9. doi: 10.1007/978-1-4899-7305-4_19.
Response to treatment, histologic progression, and survival of 127 patients with follicular lymphoma were analyzed according to histologic, clinical, and biological parameters. Histologic parameters were percentage of large cells (less than 10%, 41 patients; 10-25%, 38 patients; 25-50%, 11 patients; greater than or equal to 50%, 30 patients), percentage of diffuse areas, presence of intrafollicular proliferation or fibrosis, and mitotic scale. Eighty percent of the patients achieved complete remission (CR) with radiotherapy for localized stages and various chemotherapy regimens for disseminated stages. Three patients did not respond to treatment, and 23 were in partial remission (PR) at the end of treatment. Median survival time was 9.25 years. A constant death rate of 8% per year was observed without plateau. Histologic progression was observed in 32 patients; it occurred at a constant rate during the first six years and plateaued thereafter. Factors associated with low response rate were stage IV, B symptoms, high tumor mass, and two or more extranodal sites. Factors associated with histologic progression were bone marrow involvement and two or more extranodal sites. Factors associated with poor survival were advanced stage, two or more extranodal sites, bone marrow involvement, high lactate dehydrogenase level, and absence of interfollicular fibrosis. The percentages of large cells and diffuse areas had no influence on prognosis, nor had the type of treatment. Median survival has not been reached for CR patients and was four years for PR patients (P less than 0.0001). The LNH-84 prognostic index for aggressive lymphomas, based on tumor mass, number of extranodal sites, stage, and LDH level, is a clear-cut indicator of prognosis in follicular lymphomas too.(ABSTRACT TRUNCATED AT 250 WORDS)
根据组织学、临床和生物学参数,对127例滤泡性淋巴瘤患者的治疗反应、组织学进展和生存情况进行了分析。组织学参数包括大细胞百分比(小于10%,41例;10 - 25%,38例;25 - 50%,11例;大于或等于50%,30例)、弥漫区域百分比、滤泡内增殖或纤维化的存在情况以及有丝分裂程度。80%的患者通过局部阶段的放射治疗和播散阶段的各种化疗方案实现了完全缓解(CR)。3例患者对治疗无反应,23例在治疗结束时处于部分缓解(PR)状态。中位生存时间为9.25年。观察到每年恒定的8%的死亡率,且无平台期。32例患者出现组织学进展;在前六年以恒定速率发生,此后趋于平稳。与低反应率相关的因素为IV期、B症状、高肿瘤负荷以及两个或更多结外部位。与组织学进展相关的因素为骨髓受累和两个或更多结外部位。与生存不良相关的因素为晚期、两个或更多结外部位、骨髓受累、高乳酸脱氢酶水平以及滤泡间纤维化的缺失。大细胞百分比和弥漫区域百分比对预后无影响,治疗类型也无影响。CR患者的中位生存时间尚未达到,PR患者为四年(P小于0.0001)。基于肿瘤负荷、结外部位数量、分期和乳酸脱氢酶水平的侵袭性淋巴瘤的LNH - 84预后指数,也是滤泡性淋巴瘤预后的明确指标。(摘要截断于250字)